GREENFIELD — If a purchase agreement is approved later this year, Elanco will enter the global poultry vaccine market with the acquisition of German-based Lohmann SE.
The agreement to purchase all assets of Lohmann and its subsidiary, Lohmann Animal Health, was announced Monday; however, terms of the deal were not disclosed.
The move is in line with a strategy statement announced in January 2013 that Greenfield-based Elanco’s parent, Eli Lilly and Co., would not sell off its animal health division, but expand it with acquisitions to bolster losses the company might face in its core pharmaceutical business due to the expiration of the company’s patents on Zyprexa and Cymbalta.
Lohmann, with roots that go back to 1967, has headquarters in Cuxhaven, Germany. It is a leader in the global supply of poultry vaccines and markets animal feed additives, according to a company news release.